This interview is part of our new AI in Healthcare series, where we interview the world's top thought leaders on the front lines of the intersections between AI and healthcare.
In this interview, we speak with Richard Lin, CEO of Thryve, to understand how his company is using AI to transform healthcare, and what the future of the industry holds.
1. What’s the story behind Thryve? Why and how did you begin?
RL: About three years ago, I took antibiotics and ended up hospitalized. I pursued multiple medical professionals due to ongoing symptoms but all of them dismissed my concerns and prescribed antidepressants. Through this process, I met many people with chronic health issues online that mentioned I might have a serious gut infection from these antibiotics. I got tested for a specific bacteria that came back positive. I was later treated and felt much better with the abatement of symptoms. This spurred Richard to research the microbiome (bacteria, yeast, and viruses) that reside inside our bodies and he came to the realization of the importance of our microbiome to health. That's how Thryve came to be.
2. Please describe your use case and how Thryve uses artificial intelligence:
RL: Thryve utilizes natural language processing and machine learning on 50,000+ microbiome research journals to summarize and create metadata on tens of thousands of species of bacteria for highly detailed content/recommendations for consumers. Thryve also utilizes machine learning on their large dataset of microbiome and health data for details, recommendations, and accuracy in personalization.
3. Could you share a specific customer/user that benefits from what you offer? What has Thryve done for them?
RL: Our largest use cases are digestive problems (IBS, IBD, Constipation), Metabolic (Overweight, Diabetes), Autoimmunity, and Mental Health (Depression/Anxiety). We've seen symptom improvement anywhere from three days to seven months, where customer's quality of life has drastically improved and they are able to participate in and enjoy life again.